Congress designates September as ovarian cancer awareness month, highlights racial disparities
H.Res. 775 — Supporting the designation of September 2025 as "National Ovarian Cancer Awareness Month". · Filed by Rosa DeLauro (D-CT) · 2 cosponsors · Introduced Sep 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution designates September 2025 as 'National Ovarian Cancer Awareness Month' to increase public awareness of ovarian cancer symptoms, risk factors, and the need for early detection and genetic testing. The bill documents that ovarian cancer is the fifth-leading cause of cancer death in women, lacks a reliable early detection test, and disproportionately affects Black women and underserved communities, and calls on the House to support awareness efforts and research funding.
Why we flagged it
This is a straightforward commemorative resolution supporting a designated awareness month for a serious public health condition. It contains no legislative mechanism, appropriation, or regulatory change—only a statement of support for awareness efforts and implicit endorsement of research and equity goals.
What the text implies
- The resolution's emphasis on disparities in Black women's outcomes and underserved communities may create political pressure for targeted federal funding or policy changes in cancer research and healthcare access, though the resolution itself does not mandate action.
- By highlighting the lack of an early detection test and low genetic testing compliance, the resolution implicitly advocates for increased federal investment in ovarian cancer research and clinical guideline implementation, which could influence appropriations decisions.
- The resolution documents that approximately 80% of ovarian cancer cases are detected at advanced stages due to lack of early detection tests and vague symptoms, which may support future arguments for regulatory changes or FDA initiatives around diagnostic development.
Who it affects
This resolution raises public awareness of a serious health threat, documents disparities in outcomes across racial and socioeconomic groups, and advocates for improved access to genetic testing and clinical care. It imposes no costs on citizens and supports health equity and disease prevention.
Who stands to gain
- pharmaceutical companies (cancer treatment and genetic testing)
- cancer research organizations
- healthcare providers and oncology clinics
Named in the bill
Ovarian Cancer Research Alliance, National Comprehensive Cancer Network, Society of Gynecologic Oncology, National Cancer Institute, National Academy of Medicine, American Cancer Society, BMY (Bristol Myers Squibb), GH (Guardant Health), PFE (Pfizer), DVA (DaVita), JNJ (Johnson & Johnson)
Where it stands
2 cosponsors: 1 Democrats, 1 Republicans.
- Sep 30, 2025 — Referred to House Committee on Oversight and Government Reform · Congress.gov: “Referred to the House Committee on Oversight and Government Reform”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 6, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress designates September as ovarian cancer awareness month, highlights racial disparities” QuorumCivic. https://share.quorumcivic.app/bill/119/hres775 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.